GENinCode test products have been developed to help physicians make improved clinical decisions.By delivering comprehensive risk assessment we are able to stratify patients and identify the most appropriate treatment pathways aligned with clinical guidelines to ensure optimal outcome.
Stay up to date on our shareholder news, view our financial performance and shareholder services.
Interim Results to 30 June 2023 (pdf)
Annual Report (pdf)
Interim Results to 30 June 2022 (pdf)
Interim Results to 30 June 2021 (pdf)
